Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03884829 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
A Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03884829 is a Phase 1 study that was terminated before completion, run by Cyclacel Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT03884829, a Phase 1 study, was terminated before completion, sponsored by Cyclacel Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes
Interventions
- DRUG CYC140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03884829
The ClinicalTrials.gov registry entry for NCT03884829 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CYC140 is the first listed.
NCT03884829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03884829 about?
NCT03884829 is a clinical study titled "A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS". A Phase I Pharmacologic Study of CYC140, a polo-like kinase 1 inhibitor, in Patients with Advanced Leukemias or Myelodysplastic Syndromes
What is the current status of trial NCT03884829?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-03-25. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT03884829?
The interventions under investigation include: CYC140 (DRUG).
Who is sponsoring clinical trial NCT03884829?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.